SystImmune reports Phase 1 activity for BL‑M14D1 in small‑cell lung cancer at ASCO26

Another major advance vs cancer! @ascocancer.bsky.social #ASCO26 Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda) ascopubs.org/doi/10.1200/...

Join MSK medical oncology fellow Dr. Ziad El Bakouny at #ASCO26 for a poster on the clinical and genomic factors that drive immune-related side effects across cancer types. @mskcancercenter.bsky.social 🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/4wY4ue6

🎤 Today at #ASCO26: EORTC Quality of Life Group member Vesna Bjelic-Radisic presents new insights on the @eortc.org QLQ‑OV28 update. Advancing how we measure #QualityofLife for patients with #OvarianCancer. 🔗 www.asco.org/abstracts-pr... #GivingVoice2Patients #CancerResearch @ascocancer.bsky.social

Join MSK gastrointestinal medical oncologist Dr. Ghassan Abou-Alfa at #ASCO26 as he presents efficacy and safety results from the phase 3 EMERALD-3 study. 🕒 Monday, June 1 | 9:45 a.m. CDT Learn more: https://bit.ly/4ecVY3A

Happening this morning at #ASCO26! Fred Hutch Drs. Shailender Bhatia, Heather Cheng and Noam Kopmar are presenting their research findings. https://bit.ly/4wTwhwp

Today at #ASCO26, Waqas Haque, MD, MPH will be presenting on the clinical development of AI-enabled therapeutic assets. Stop by his poster to learn about how AI-enabled drug discovery is moving into clinical trials. #ArtificialIntelligence #DrugDiscovery

Incredible finding for treatment of previously treated metastatic pancreatic cancer using targeted therapy. Exciting to see more and more targeted agents emerge that we can use to help treat patients #ASCO26

Don’t miss the final day of events at the TEC Lounge! We’re hosting 5 sessions today in Hall C focused on leadership, clinical trials, & the first 6 months on the job. Make the most of these sessions at #ASCO26! 🤝 Full schedule: https://bit.ly/42k0ZRk

Wonderful evening at #ASCO26 connecting with colleagues and catching up with friends at our annual reception. More photos to come! @ascocancer.bsky.social

Start off your #ASCO26 Monday morning with two NRG Oncology #GynecologicCancer trials highlighted during poster sessions↪️NRG-GY036 with Dr. Ying Liu and NRG-GY037 with Dr. Jyoti Mayadev.

We’re back with more #ASCO26 coverage! Today we kick-off with the latest results from the POTOMAC study presented by Maria de Santis

Tomorrow is the final day at #ASCO26 and we're ending strong! Dr. Erika Hamilton presents on HER2-targeted combination therapy in metastatic breast cancer. #InnovationInCancerCare #SCRI #ASCO26 www.scri.com/asco/

It’s our last day at #ASCO26! Visit us in booth 13032 to learn more about registration and submitting an abstract for #SITC26. #immunotherapy #cancerresearch

Minimal residual disease remains one of the biggest challenges in #OvarianCancer. At #ASCO2026, Dr Helen Clark from our Targeting MRD in Ovarian Cancer TeamLab presents work evaluating how ctDNA may enhance detection of high-risk minimal residual disease.